The recommended dose is between 2.68 x 10⁹ to 10 x 10⁹ MAGE-A4 T cell receptor (TCR) positive T cells administered as a single intravenous infusion.

TECELRA is provided as a single dose for infusion in one or more infusion bag(s). Verify the number of bags received for the indicated dose prior to preparation for infusion.

Receipt of TECELRA

Plan for TECELRA to arrive prior to beginning lymphodepleting chemotherapy.

Ensure storage conditions in vapor phase of liquid nitrogen (≤ -130°C).

TECELRA is shipped directly to the healthcare facility in the vapor phase of a liquid nitrogen shipper. Upon receipt of TECELRA confirm the patient’s identifiers on the metal cassette and product bag.

Inspect the product for obvious signs of damage and contact Adaptimmune at 1-855-24MYADAP (1-855-246-9232) if any anomalies are identified at the time of receipt.

Transfer TECELRA in the original packaging, containing the cassette(s) protecting the infusion bag(s), to onsite storage at ≤ -130°C before the shipper expires.

Store TECELRA in a manner that is consistent with How Supplied/Storage and Handling (16). If unforeseen circumstances prevent proper storage of TECELRA consistent with How Supplied/Storage and Handling (16), contact Adaptimmune at 1- 855-24MYADAP (1-855-246-9232) to arrange for return shipment.

Preparing Patient for TECELRA Administration

Confirm availability of TECELRA at the healthcare facility prior to starting the lymphodepleting chemotherapy regimen.

Match the patient’s identity with the patient identifiers on the TECELRA cassette(s) and infusion bag(s). Do not infuse TECELRA if the information on the patient-specific label(s) does not match the intended patient.

Administer a lymphodepleting chemotherapy regimen of fludarabine 30 mg/m2/day intravenously for 4 days starting on the seventh day before TECELRA infusion (Day-7 to Day -4) and cyclophosphamide 600 mg/m2/day intravenously for 3 days starting the seventh day before TECELRA infusion (Day -7 to Day -5).

Refer to fludarabine prescribing for information on fludarabine dosage in patients with renal impairment.

Short-acting or pegylated granulocyte-colony stimulating factor (G-CSF) may be administered at the discretion of the physician, and according with institutional standards, from 24 hours after last day of lymphodepleting chemotherapy (from Day -3) until resolution of neutropenia.

Premedication

Premedicate with an H1-antihistamine and acetaminophen according to institutional standard practice, approximately 30-60 minutes prior to TECELRA infusion.

Avoid prophylactic systemic corticosteroids, as it may interfere with the activity of TECELRA.

Preparation of TECELRA for Administration

Do not thaw the product until it is ready to be used. Coordinate the timing of TECELRA thaw and infusion. Confirm infusion time in advance and adjust the start time of TECELRA thaw such that it will be available for infusion when the patient is ready.

A TECELRA dose may be contained in one or more infusion bag(s). Verify the number of bags received for the indicated dose prior to preparation of TECELRA for infusion. If more than one bag will be infused for the treatment dose, thaw and administer the contents of each infusion bag completely before proceeding to thaw and infuse the contents of the next infusion bag.

1. Confirm patient identity. Prior to TECELRA preparation, match the patient’s identity with the patient identifiers on each TECELRA cassette. Do not remove the TECELRA infusion bag(s) from the cassette(s) if the information on the patient-specific label does not match the patient’s identity. Contact Adaptimmune at 1-855-24MYADAP (1-855-246-9232) if there are any discrepancies between the labels and the patient identifiers.

2. Once patient identity is confirmed, remove TECELRA infusion bag(s) from the cassette(s) and check that the patient identifiers on the cassette label match the patient identifiers on the bag label. Contact Adaptimmune at 1-855-24MYADAP (1-855-246-9232) if there are any discrepancies between the patient identifiers on the cassette and bag labels.

3. Inspect the infusion bag for any breaches of container integrity such as breaks or cracks before thawing. If the bag is compromised, do not infuse the contents and call Adaptimmune at 1-855-24MYADAP (1-855-246-9232)

4. Place the infusion bag inside a second sealable ,preferably sterile bag per institutional standard practice.

5. Thaw the infusion bag at approximately 37°C using a water bath or dry thaw method, until there is no visible ice in the infusion bag.

6. Gently mix the contents of the bag by massaging, to disperse visible cell clumps. Small clumps of cellular material should disperse with gentle manual massaging. Do not infuse TECELRA if clumps are not dispersed. Call Adaptimmune at 1- 855-24MYADAP (1-855-246-9232).

7. Keep TECELRA at ambient temperature (20°C to 25°C) once thawed. Do not pre-filter into a different container, wash, spin down, or resuspend TECELRA in new media prior to infusion.

8. Administer within one hour.

TECELRA Administration

9. Do not use a leukodepleting filter.

10. Follow universal precautions and local biosafety guidelines for handling and disposal of TECELRA to avoid potential transmission of infectious diseases, due to the presence of human blood cells that are genetically modified with replication incompetent, self-inactivating lentiviral vector.

11. Confirm patient identity with the patient identifiers on the infusion bag(s). Do not infuse TECELRA if the information on the patient-specific label does not match the intended patient. Call Adaptimmune at 1-855-24MYADAP (1-855-246-9232). Prime the tubing of the infusion set with 0.9% sodium chloride solution prior to infusion.

12. Administer the TECELRA infusion bag via intravenous infusion within one hour. Administer the entire contents of the TECELRA infusion bag.

13. After the entire contents of the TECELRA infusion bag are infused, rinse the infusion bag with approximately 50mL 0.9% sodium chloride solution to ensure all product is delivered.

14. If more than one infusion bag has been received, administer the content of each infusion bag completely before proceeding to thaw and infuse the content of the next infusion bag, following steps 1-14 for all subsequent infusion bags.

Cytokine release syndrome (CRS), including potentially life-threatening reaction has been observed following administration of TECELRA. CRS occurred in 75% of patients, 2% of whom had Grade ≥ 3 CRS. The median time to onset was 2 days (range: 1 to 5 days) and the median time to resolution was 3 days (range: 1 to 14 days). The most common symptoms were fever (97%), tachycardia (52%), hypotension (30%), nausea/vomiting (21%) and headache (15%) [see Adverse Reactions (6)]. Management for CRS (including Grade 1) was tocilizumab (55%). Thirteen patients received one dose and five patients received more than one dose. Of the five patients who received more than one dose of tocilizumab, two patients received dexamethasone in addition to tocilizumab.

Ensure that healthcare providers administering TECELRA have immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions.

During and following TECELRA administration, closely monitor patients for signs and symptoms of CRS. Following treatment with TECELRA, monitor patients for at least 7 days at the healthcare facility for CRS. Continue to monitor patients for CRS for at least 4 weeks following treatment with TECELRA. Counsel patients to seek medical attention should signs or symptoms of CRS occur. At the first sign of CRS, immediately evaluate patient for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.

Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) has been observed following administration of TECELRA. One patient (2%) had Grade 1 ICANS. Time to onset was two days and time to resolution was one day. Symptoms included mild mental status changes. Other symptoms may include disorientation to time and place, mild drowsiness, mild inattention. Severe symptoms may include altered level of consciousness, seizures, cerebral edema, impairment of cognitive skills, progressive aphasia, motor weakness.

Ensure that healthcare providers administering TECELRA have immediate access to medications and resuscitative equipment to manage ICANS.

During and following TECELRA administration, closely monitor patients for signs and symptoms of ICANS. Following treatment with TECELRA, monitor patients for at least 7 days at the healthcare facility for ICANS. Continue to monitor patients for ICANS for at least 4 weeks following treatment with TECELRA. Counsel patients to seek medical attention should signs or symptoms of ICANS occur. At the first sign of ICANS, immediately evaluate patients for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.

Effect on Ability to Drive and Use Machines

Due to the potential for neurologic events, including dizziness and presyncope, patients receiving TECELRA are at risk for altered or decreased coordination in the 4 weeks following infusion.

Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.

Patients may exhibit severe cytopenias, including neutropenia and thrombocytopenia [see Adverse Reactions (6)].

Patients exhibited anemia, neutropenia, and/or thrombocytopenia for several weeks following lymphodepleting chemotherapy and TECELRA infusion. Patients with Grade ≥ 3 cytopenia not resolved by week 4 included anemia (9%), neutropenia (11%), and thrombocytopenia (5%). The median time to resolution was 7.3 weeks (range: 6.1 to 8.4 weeks) for anemia, 9.3 weeks (range: 6.4 to 12.3 weeks) for neutropenia and 6.3 weeks (range: 6.1 to 6.4 weeks) for thrombocytopenia.

Monitor blood counts after TECELRA infusion. Manage cytopenia with growth factor and blood product transfusion according to local institutional guidelines/clinical practice.

Infections may occur following lymphodepleting chemotherapy and TECELRA infusion. Infections (all grades) occurred in 32% of patients with synovial sarcoma. Grade 3 or higher infections occurred in 14% of patients.

Do not administer TECELRA to patients with active infections and/or inflammatory disorders.

Monitor patients for signs and symptoms of infection before and after TECELRA infusion and treat patients appropriately.

Febrile neutropenia was observed in patients after TECELRA infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids and other supportive care, as medically indicated.

Viral reactivation has occurred in patients following treatment with TECELRA. Perform screening for Epstein-Barr Virus, Cytomegalovirus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, and any other infectious agents if clinically indicated. Consider antiviral therapy to prevent viral reactivation per local guidelines.

Patients treated with TECELRA may develop secondary malignancies or recurrence of their cancer. Monitor for secondary malignancies.

In the event that a secondary malignancy occurs, contact Adaptimmune at 1-855-24MYADAP (1-855-246-9232) to obtain instructions on patient samples to collect for testing.

Serious hypersensitivity reactions, including anaphylaxis, may occur due to dimethyl sulfoxide (DMSO) in TECELRA. Observe patients for hypersensitivity reactions during infusion.

The lentiviral vector used to make TECELRA has limited, short spans of genetic material which are identical to HIV. Therefore, some commercial HIV nucleic acid tests may yield false-positive results in patients who have received TECELRA.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described in this section reflects the exposure to TECELRA in 44 patients with advanced synovial sarcoma treated in the SPEARHEAD-1 clinical trial (Cohort 1). Patients with synovial sarcoma received TECELRA across a dose of 2.68 x 10⁹ to 10 x 10⁹ MAGE-A4 TCR positive T cells [see Clinical Studies (14)].

Serious adverse reactions occurred in 52% of patients with synovial sarcoma. The most common serious adverse reactions (occurring in ≥ 5%) included CRS (9%) and pleural effusion (7%).

Table 1 summarizes adverse reactions that occurred in at least 10% of patients.

Table 1. Adverse Reactions Occurring in ≥10% of Patients in SPEARHEAD-1 (Cohort 1)

SOC Grouped Term	(N=44)
	All Grades n (%)	Grade ≥ 3 n (%)
Investigations
Weight decreased	5 (11)	1 (2)
Gastrointestinal disorders
Nausea	29 (66)	1 (2)
Vomiting	16 (36)	0 (0)
Constipation	14 (32)	0 (0)
Abdominal pain	11 (25)	2 (5)
Diarrhea	9 (21)	0 (0)
General disorders and administration site conditions
Fatigue	15 (34)	0 (0)
Pyrexia	14 (32)	1 (5)
Non-cardiac chest pain	10 (23)	1 (2)
Chills	7 (16)	0 (0)
Edema	9 (21)	0 (0)
Asthenia	7 (17)	1 (2)
Chest pain	6 (14)	0 (0)
Immune system disorders
Cytokine Release SyndromeAs per American Society for Transplantation and Cellular Therapy (ASTCT) criteria1	33 (75)	1 (2)
Infections and infestations
Any infectionAny infection includes all infection terms under the 'Infections and infestations' System Organ Class	14 (32)	6 (14)
Nervous system disorders
Headache	8 (18)	1 (2)
Dizziness	5 (11)	0 (0)
Metabolism and nutrition disorders
Decreased appetite	10 (23)	1 (2)
Musculoskeletal and connective tissue disorders
Back pain	9 (21)	2 (5)
Pain in extremity	6 (14)	0 (0)
Respiratory, thoracic, and mediastinal disorders
Dyspnea	11 (25)	2 (5)
Cough	8 (18)	0 (0)
Vascular disorders
Hypotension	9 (21)	0 (0)
Hypertension	7 (16)	1 (2)
Cardiac disorders
Sinus Tachycardia/ Tachycardia	9 (21)	0 (0)
Skin and subcutaneous tissue disorders
Alopecia	6 (14)	0 (0)

Other clinically important adverse reactions occurring in patients receiving TECELRA include Grade 1 ICANS reported in one patient (2%).

Table 2. Laboratory AbnormalitiesAbnormalities are laboratory values that were considered an adverse event Worsened from Baseline in ≥10% of Patients in SPEARHEAD-1 (Cohort 1)

Laboratory Abnormalities	(N=44)
	All Grades n (%)	Grade 3 or 4 n (%)
Grading based on NCI CTCAE version 5.0.
Lymphocyte count decreased	43 (98)	43 (98)
Neutrophil count decreased	42 (96)	40 (91)
White blood cell decreased	42 (96)	38 (86)
Red blood cell decreased	42 (96)	14 (32)
Platelet count decreased	36 (82)	9 (21)
Alanine aminotransferase increased	20 (46)	2 (5)

Risk Summary

There are no available data with TECELRA use in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with TECELRA to assess whether it can cause fetal harm when administered to a pregnant woman. It is not known if TECELRA has the potential to be transferred to the fetus and cause fetal toxicity. Therefore, TECELRA is not recommended for women who are pregnant, and pregnancy after TECELRA administration should be discussed with the treating physician. Report all pregnancies following treatment with TECELRA to Adaptimmune at 1-855-24MYADAP (1-855-246-9232).

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Risk Summary

There is no information regarding the presence of TECELRA in human milk, the effect on the breastfed infant, and the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TECELRA and any potential adverse effects on the breastfed infant from TECELRA or from the underlying maternal condition.

Pregnancy Testing

Verify pregnancy status of females with reproductive potential prior to starting treatment with TECELRA.

Contraception

There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with TECELRA.

The safety and effectiveness of TECELRA have not been established in pediatric patients.

Of the 44 patients with synovial sarcoma in the SPEARHEAD-1 study that received TECELRA, 6.8% were 65 years of age or older. Clinical studies of TECELRA did not include sufficient numbers of patients aged 65 and over to conclude whether they respond differently from younger patients.

TECELRA is a genetically modified autologous T cell immunotherapy consisting of CD4 and CD8 positive T cells transduced with a self-inactivating LV to express an affinity- enhanced TCR specific for human MAGE-A4 on the cell surface.

The TCR recognizes an HLA-A*02 restricted MAGE-A4 peptide. MAGE-A4 is an intracellular cancer-testis antigen that has restricted expression in normal tissues and is expressed in synovial sarcoma. Antigen-specific activation of TECELRA via TCR- peptide-HLA-A*02 complex results in T cell proliferation, cytokine secretion, and killing of MAGE-A4/HLA-A*02 expressing synovial sarcoma cells.

In patients with synovial sarcoma who were treated with TECELRA, serum concentrations of cytokines and other soluble factors involved in cellular homeostasis, T cell activation, and inflammation (e.g. IFNγ, IL-6, IL-8, IL-15, and IL-2Rα) increased post-infusion, peaking between Days 3-8.

TECELRA exhibited an initial engraftment and expansion phase followed by contraction, and then persistence. High inter-individual variability was observed.

The pharmacokinetics of TECELRA in patients with synovial sarcoma are summarized in Table 3.

Table 3. Pharmacokinetics of Afamitresgene Autoleucel in SPEARHEAD-1 (Cohort 1)All patients received a dose within the range of 2.68 x 10⁹ to 10 x 10⁹ MAGE-A4 TCR positive T cells.

PK Parameter	N	Statistics	Value
tmax (day)	44	Median (range)	7 (1-89)
Cmax (DNA copies/μg)	44	Geometric mean (CV%)	189269 (109.1%)
AUC0-7D (day*DNA copies/μg)	44	Geometric mean (CV%)	729653 (110.8%)
AUC0-28D (day*DNA copies/μg)	41	Geometric mean (CV%)	3074205 (164.7%)
AUC0-3M (day*DNA copies/μg)	35	Geometric mean (CV%)	4988965 (242.7%)
AUC0-6M (day*DNA copies/μg)	33	Geometric mean (CV%)	6784047 (313.4%)

Specific Populations

The pharmacokinetics of afamitresgene autoleucel (C_max, AUC_0-7D, AUC_0-28D, AUC_0-3M, AUC_0-6M) were not impacted by body weight, body mass index, sex, age (range: 19 to 76 years), and baseline tumor sum of longest diameter (SLD).

Hepatic and renal impairment studies of TECELRA were not conducted.

No carcinogenicity or genotoxicity studies have been conducted with TECELRA.

A genomic insertion site analysis was performed on TECELRA products from five patients. There was no evidence for preferential integration near genes of concern. No studies have been conducted to evaluate the effects of TECELRA on fertility.